ClinicalTrials.gg
RecruitingNCT03977233Updated Jan 13, 2026

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

A Phase 2 interventional study of Oxaliplatin and Leucovorin in Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas and Pancreatic Cancer, Adult, sponsored by UNC Lineberger Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Primary conditionPancreatic cancer, adultRegistry: Pancreatic NeoplasmsReclassifiedWhy we changed it
Registry
Pancreatic Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pancreatic cancer, adult
Why
  1. The study's listed conditions name Pancreatic cancer, adult, a narrower term within Pancreatic Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by UNC Lineberger Comprehensive Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2019; still recruiting 7 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (removed). However, not all types of PDACs are resectable, especially if they are close to important structures like blood vessels or intestines. These types of PDACs are treated with chemotherapy such as FOLFIRINOX. Research studies showed that chemotherapy after surgical resection of PDAC tumors reduced the risk of the cancer returning.

Chemotherapy is used to treat PDAC that has not spread outside of the pancreas and is not resectable. FOLFIRINOX is a chemotherapy treatment that combines multiple chemotherapeutic agents, including oxaliplatin, leucovorin, irinotecan, and 5-FU. Patients receive these agents by intravenous infusion. Of these drugs, 5-FU requires you to return home with a chemotherapy pump that will deliver chemotherapy over 46 hours. This regimen has been studied in pancreatic cancer that has been removed with surgery as a method for preventing the cancer from returning. Studies showed FOLFIRINOX chemotherapy reduced the risk of cancer returning and increased patients survival. In this study, researchers want to know if FOLFIRINOX chemotherapy given before surgery will make the cancer easier to remove with surgery and increase the chances of the cancer staying away after surgery.

Researchers have shown that pancreatic cancers are not all the same when you look at the DNA and RNA that is inside a pancreatic cancer cell.

Depending on the expression of different genes in a cancer cell, some pancreatic cancers may respond differently to chemotherapy. In this study researchers want to know if FOLFIRINOX chemotherapy can change the genetic profile of the cancer. This will be studied by obtaining a biopsy of the cancer before the start of chemotherapy, and after 8 treatments of chemotherapy. They will also study cancer cells that will be collected from blood samples.

Read the detailed description

This is a single arm, phase II clinical trial designed to assess the impact of tumor and stromal molecular subtypes on the efficacy of neoadjuvant FOLFIRNOX in untreated subjects with resectable, borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma (PDAC). Subjects will undergo an EUS-guided core biopsy of the pancreas prior to treatment and after cycle 8 of FOLFIRINOX. Imaging will be performed after every 4 cycles of chemotherapy (8 weeks) and reassessed for resectability after 12 cycles. If patients show a response to treatment that is deemed by the surgical oncologist to be amenable to resection, surgery can be pursued after 8 cycles of therapy. In this case, the remaining 4 cycles of treatment will be given after surgery.

Duration of Therapy:

In the absence of treatment delays due to adverse events, treatment may continue until:

  • Disease progression,
  • Inter-current illness that prevents further administration of treatment,
  • Unacceptable adverse event(s),
  • Subject decides to withdraw from the study, or
  • General or specific changes in the subject's condition render the subject unacceptable for further treatment in the judgment of the investigator.

Duration of Follow Up:

- Subjects will be followed for 36 months after removal from study treatment or until death, whichever occurs first. Subjects removed from study treatment for unacceptable adverse events will be followed until resolution or stabilization of the adverse event.

02

Conditions studied

  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Cancer of Pancreas
  • Pancreatic Cancer, Adult
  • Pancreas Adenocarcinoma
  • Pancreatic Neoplasms
  • Pancreatic Cancer Non-resectable
  • Pancreatic Cancer Resectable

Browse trials for

Keywords

  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cancer Non-resectable
  • Pancreatic Cancer Resectable
  • neoadjuvant FOLFIRNOX
  • FOLFIRINOX
  • Pancreatic Cancer, Adult
03

In context

Pancreatic cancer, adult Reclassified

25 studies on the registry are indexed under Pancreatic cancer, adult; 18 are open to participants now.

This study's planned enrollment of 45 is below the median of 90 across 17 interventional studies indexed under Pancreatic cancer, adult.

Browse Pancreatic cancer, adult studies →

Lead sponsor

UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 431 studies on the registry; 96 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Compared within Pancreatic cancer, adult, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pancreatic Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained to participate in the study and HIPAA authorization for release of personal health information.
  • or cytologically confirmed adenocarcinoma of the pancreas with no evidence of distant disease.
  • Subject has no evidence of co-morbidities precluding the potential to undergo surgical resection of PDAC as determined by surgical investigator.
  • Subjects must be willing to undergo a mandatory pre- and post-treatment EUS guided core of the pancreatic mass.
  • Measurable or non-measurable but evaluable (as determined by version 1.1 [RECIST 1.1]) resectable, borderline resectable or unresectable locally advanced PDAC.
  • Subject has adequate performance status as defined by performance status 0 or 1.
  • Subject has received no prior chemotherapy or chemoradiotherapy for pancreatic cancer. Subjects have not previously received surgery to remove pancreatic cancer.
  • Age ≥ 18 years of age.
  • Subject has adequate organ function at study entry.
  • Subject has of at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Subject has any evidence of local recurrence or pancreatic cancer.
  • Other within the past 5 years except for adequately treated cervical or vulvar carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1).
  • Subject has to 5FU, oxaliplatin or other platinum agent, or irinotecan or to their .
  • Subject has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.
  • Participation in any drug study within 4 weeks preceding the start of study treatment. Subjects are not permitted to participate in another investigational drug study while being treated on this protocol. Subjects participating in other clinical trials that are receiving SOC FOLFIRINOX are permitted on study.
  • Subject has current evidence of any condition that makes participating in this study not in the best interest of the subject, including but not limited to:

    • Myocardial infarction within the past 6 months
    • (NYHA) Class III or IV heart disease
    • Active infection requiring IV antibiotics
  • Subject has a history of or suspected Gilbert's syndrome or known homozygosity for UGT1A1*28 polymorphism (baseline testing not required).
  • Subject has sensory peripheral neuropathy grade ≥ 2.
  • Major surgery, open or significant traumatic injury within 4 weeks of first study drug.
  • Subject is unable or unwilling to discontinue use of ketoconazole or St John's wort. Use of phenytoin, carbamazepine, phenobarbital, rifampin and rifabutin is discouraged, but not . If subjects require phenytoin, carbamazepine or phenobarbital monitoring of drug levels is suggested during the study.
  • Subject is pregnant or lactating.
  • Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    SingleArm: FOLFIRINOX

    Subjects will receive FOLFIRINOX as an outpatient every 14 days per community standards of medical care. Protocol-based therapy will continue for 12 cycles (24 weeks) or until disease progression, unacceptable toxicity, study withdrawal, or subject death. Subjects will have the option of surgical resection after 8 cycles of therapy if repeat scans show evidence of resectable disease. The starting doses for mFOLFIRINOX regimen are: oxaliplatin 85 mg/m2, followed by leucovorin 400 mg/m2 given simultaneously with irinotecan 180mg/m2, followed by 5FU 400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion.

    Drug: Oxaliplatin · Drug: Leucovorin · Drug: Irinotecan Hydrochloride · Drug: 5-FU

Interventions

  • 85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle

    Also known as: Eloxatin

  • 400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle

    Also known as: folinic acid

  • DrugIrinotecanStudies of IrinotecanIrinotecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle

    Also known as: Camptosar

  • DrugFluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle

    Also known as: Adrucil

06

What researchers measure

Primary outcomes

  1. Best disease control rate by Pancreatic ductal adenocarcinoma (PDAC) subtype

    To evaluate the association between PDAC tumor subtype (particularly basal-like versus classical subtype) and best disease control rate (DCR) after administration of FOLFIRINOX in subjects with non-metastatic pancreatic cancer, DCR is defined as the proportion of patients with either Complete Response (CR), partial response (PR), or stable disease (SD) as determined by RECIST 1.1, Response Evaluation Criteria In Solid Tumors Criteria. CR is defined as disappearance of all target lesions; PR as a \>=30% decrease in the sum of the longest diameter of target lesions; and SD as no response or less response than Partial or Progressive.

    Time frame: 6 months after start of treatment

Secondary outcomes

  1. Rate of resectability

    The number of patients who following treatment with FOLFIRINOX were subsequently deemed to have resectable disease and underwent surgical resection

    Time frame: 6 months after the start of treatment

  2. Overall survival

    median overall survival (OS) of all patients receiving FOLFIRINOX on study as well as in 1) resectable, 2) borderline resectable and 3) unresectable PDAC, measured from the start of treatment until death from any cause.

    Time frame: 3 years

  3. Progression free survival

    Median time from start of treatment until death or progression as defined by RECIST 1.1 Criteria, for all patients and with respect to each tumor and stroma subtype. Progressive Disease (PD), is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: 3 years

  4. best objective response rate (ORR; complete response (CR) + partial response (PR))

    Estimation of the best ORR for all patients and with respect to each tumor and stroma subtype. ORR is defined as the proportion of patients with either Complete Response (CR) or partial response (PR) as determined by RECIST 1.1, Response Evaluation Criteria In Solid Tumors Criteria. CR is defined as disappearance of all target lesions; PR as a \>=30% decrease in the sum of the longest diameter of target lesions;

    Time frame: 6 months from start of study treatment

  5. rate of drug-related grade 3 to 5 adverse events

    rate of drug-related grade 3 to 5 adverse events, assessed based upon patient reported toxicity as measured by the NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0). The CTCAE is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

    Time frame: 6 months from the start of treatment

  6. R0 resection rate

    The number of patients who underwent surgical resection and whose surgical specimens had a microscopically margin-negative resection (R0).

    Time frame: 6 months from start of treatment

  7. proportion of patients whose tumor/stroma subtype changes after treatment with FOLFIRINOX

    The proportion of patients whose tumor/stroma subtype changed from baseline after treatment with FOLFIRINOX. This will be calculated separately for tumor and stroma.

    Time frame: 6 months from start of treatment

07

Study locations

1 of 1 sites recruiting
  • University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27599, United States
    Recruiting
    • Ashwin Somasundaram, MD · Contactashwin@med.unc.edu · 919-966-5902
    • Ashwin Somasundaram, MD · Principal investigator
    • Jen Jen Yeh, MD · Principal investigator
    • Hanna Sanoff, MD, PhD · Sub investigator
    • Michael S. Lee, MD · Sub investigator
    • Cheryl Carlson, MD, PhD · Sub investigator
    • Tammy Triglianos, RN, NP · Sub investigator
    • Ugwuji Maduekwe, MD · Sub investigator
    • Hong Jin Kim, MD · Sub investigator
    • Todd Baron, MD · Sub investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2019 (actual). Primary completion is estimated for Jul 2027, 97 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2019
First posted
Jun 6, 2019
StartActual
Jun 12, 2019
Primary completionEst.
Jul 2027
CompletionEst.
Jan 2030
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03977233
Responsible party
Sponsor
First posted
Jun 6, 2019
Start date
Jun 12, 2019
Primary completion
Jul 2027 (estimated)
Completion
Jan 2030 (estimated)
Last update
Jan 13, 2026

Study contacts

Catherine Griffin, BS, BA
Contact
catherine_griffin@med.unc.edu
919-966-4432
Brian Burgess, BS
Contact
brian_burgess@med.unc.edu
919-966-4432
Ashwin Somasundaram, MD
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Leucovorin · Irinotecan · Fluorouracil

Start the discussion